<DOC>
	<DOC>NCT02658708</DOC>
	<brief_summary>This proposed study will examine feasibility and implement therapeutic bright light that is tailored to the individual's circadian typology to estimate its therapeutic effects on sleep/wake patterns and fatigue in breast cancer patients undergoing chemotherapy.</brief_summary>
	<brief_title>Bright Light on Fatigue in Women Being Treated for Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<criteria>21 years of age or older Newly diagnosed with stage IIII breast cancer Scheduled to receive 21day cycles of intravenous chemotherapy Experiencing disrupted sleep (determined by Pittsburgh Sleep Quality Index) Morning or evening types (determined by HorneOstberg MorningnessEveningness Questionnaire (MEQ) Sighted Mentally competent to consent Able to under English Concurrent malignancy Undergoing other cancer treatments Engage in shift work or travel across more than 3 time zones within 2 weeks prior to study Known history of seasonal affective disorder or substance abuse Current diagnosis of major Axis I psychiatric disorders, neurological impairments, or muscular dystrophies Regularly use steroid or other immunosuppressive medications Take prescribed sedative hypnotics or sleep medications because these conditions may affect fatigue and/or sleep/wake patterns. Have eye conditions (glaucoma or retinal disease), problems triggered by bright light (e.g. migraine), or take photosensitizing medications (e.g. some porphyrin drugs, antipsychotics, antiarrhythmic agents)</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>